New directions in the experimental therapy of tick-borne encephalitis

0572867 - BC 2024 RIV NL eng J - Článek v odborném periodiku
Eyer, Luděk - Seley-Radtke, K. - Růžek, Daniel
New directions in the experimental therapy of tick-borne encephalitis.
Antiviral Research. Roč. 210, JAN (2023), č. článku 105504. ISSN 0166-3542. E-ISSN 1872-9096
Grant CEP: GA ČR(CZ) GF21-05445L; GA ČR(CZ) GA20-14325S
Institucionální podpora: RVO:60077344
Klíčová slova: Tick-borne encephalitis * Tick-borne encephalitis virus * Antivirals * Monoclonal antibodies * Immunotherapy
Obor OECD: Immunology
Impakt faktor: 7.6, rok: 2022
Způsob publikování: Omezený přístup
https://www.sciencedirect.com/science/article/pii/S016635422200273X?via%3Dihub

Tick-borne encephalitis (TBE) is a potentially fatal disease common in much of Europe and Asia. There is no specific therapy for the treatment of TBE patients. However, several efforts are being made to develop small molecules that specifically interfere with the life cycle of TBE virus. In particular, recently various nucleoside analogues that can inhibit the viral replicase, such as the RNA-dependent RNA polymerase or viral methyl-transferases, have been explored. In addition, human or chimeric (i.e., structural chimeras that combine mouse variable domains with human constant domains) monoclonal antibodies with promising potential for postexposure prophylaxis or early therapy have been developed. This review summarizes the latest directions and experimental approaches that may be used to combat TBE in humans.
Trvalý link: https://hdl.handle.net/11104/0343708